Amgen, Inc. (NASDAQ:AMGN) Shares Sold by Rosenbaum Jay D.

Share on StockTwits

Rosenbaum Jay D. decreased its position in Amgen, Inc. (NASDAQ:AMGN) by 2.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,416 shares of the medical research company’s stock after selling 210 shares during the quarter. Amgen accounts for about 3.3% of Rosenbaum Jay D.’s investment portfolio, making the stock its 6th largest holding. Rosenbaum Jay D.’s holdings in Amgen were worth $1,735,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Bangor Savings Bank lifted its stake in Amgen by 2.1% during the first quarter. Bangor Savings Bank now owns 2,682 shares of the medical research company’s stock worth $510,000 after purchasing an additional 55 shares during the last quarter. Carroll Financial Associates Inc. lifted its stake in Amgen by 0.8% during the second quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock worth $1,370,000 after purchasing an additional 58 shares during the last quarter. Lincoln Capital Corp lifted its stake in Amgen by 0.3% during the second quarter. Lincoln Capital Corp now owns 21,483 shares of the medical research company’s stock worth $3,959,000 after purchasing an additional 58 shares during the last quarter. Slow Capital Inc. lifted its stake in Amgen by 0.4% during the second quarter. Slow Capital Inc. now owns 13,799 shares of the medical research company’s stock worth $2,543,000 after purchasing an additional 58 shares during the last quarter. Finally, CWM LLC lifted its stake in Amgen by 1.8% during the second quarter. CWM LLC now owns 3,271 shares of the medical research company’s stock worth $603,000 after purchasing an additional 59 shares during the last quarter. 78.96% of the stock is owned by institutional investors.

AMGN has been the topic of several research analyst reports. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a research note on Friday, August 9th. Cowen restated a “buy” rating and set a $229.00 price objective on shares of Amgen in a research note on Wednesday, May 1st. Oppenheimer raised their price objective on Amgen from $210.00 to $230.00 and gave the stock an “outperform” rating in a research note on Tuesday. Mizuho restated a “buy” rating and set a $208.00 price objective on shares of Amgen in a research note on Monday, July 1st. Finally, BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Nine investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $211.44.

In related news, Director R Sanders Williams sold 425 shares of Amgen stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total transaction of $77,792.00. Following the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at $2,990,141.44. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $175.68, for a total value of $351,360.00. Following the transaction, the director now directly owns 16,219 shares in the company, valued at $2,849,353.92. The disclosure for this sale can be found here. Insiders have sold 4,425 shares of company stock worth $804,312 over the last three months. Corporate insiders own 0.25% of the company’s stock.

Shares of AMGN traded up $1.77 during trading hours on Thursday, reaching $200.64. 94,715 shares of the company’s stock traded hands, compared to its average volume of 3,546,323. The company has a market cap of $119.83 billion, a price-to-earnings ratio of 13.94, a price-to-earnings-growth ratio of 2.42 and a beta of 1.19. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $211.90. The stock has a fifty day simple moving average of $183.21.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period last year, the company earned $3.83 earnings per share. On average, research analysts forecast that Amgen, Inc. will post 14.25 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Wednesday, August 14th. Amgen’s dividend payout ratio (DPR) is 40.28%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: What factors cause inflation to rise?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.